Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics
Summary
The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.
What changed
The USPTO published Corner Therapeutics' patent application covering ether lipid and ether phospholipid compounds designed to hyperactivate mammalian dendritic cells. The application includes compositions combining these compounds with pathogen recognition receptor agonists, antigens, and dendritic cells themselves.
Competitors and researchers should monitor this application to assess potential conflicts with existing or planned patents and evaluate freedom-to-operate considerations in the dendritic cell activation space.
What to do next
- Monitor for patent prosecution updates and potential claims
- Review pending claims for freedom-to-operate assessment
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ETHER LIPIDS FOR HYPERACTIVATION OF MAMMALIAN DENDRITIC CELLS
Application US20260097111A1 Kind: A1 Apr 09, 2026
Assignee
Corner Therapeutics, Inc.
Inventors
Jonathan CHOW, Emily A. GOSSELIN, Dania ZHIVAKI, Kelsey FINN, Kallanthottathil RAJEEV
Abstract
The present disclosure relates to ether lipid (ETL) compounds, such as ether phospholipid (ETPL) compounds, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising an ETL, such as an ETPL, and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.
CPC Classifications
A61K 39/145 A61K 31/661 A61K 35/15 A61K 45/06 A61P 31/16 C07F 9/10 C12N 5/0639 A61K 2039/5154 A61K 2039/5252 A61K 2039/54 A61K 2039/552 A61K 2039/585
Filing Date
2023-10-18
Application No.
19120751
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.